Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GLUE Monte Rosa Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GLUE
Price (delayed)
$4.64
Market cap
$285.41M
P/E Ratio
58
Dividend/share
N/A
EPS
$0.08
Enterprise value
$243.86M
Highlights
The quick ratio has surged by 134% since the previous quarter and by 17% year-on-year
Monte Rosa Therapeutics's revenue has surged by 111% QoQ
Key stats
What are the main financial stats of GLUE
Market
Valuations
Earnings
Shares outstanding
61.51M
Market cap
$285.41M
Enterprise value
$243.86M
Price to earnings (P/E)
58
Price to book (P/B)
1.04
Price to sales (P/S)
2.39
EV/EBIT
25.77
EV/EBITDA
13.75
EV/Sales
1.53
Revenue
$159.49M
Gross profit
$159.49M
Operating income
-$2.13M
Net income
$6.15M
EBIT
$9.46M
EBITDA
$17.73M
Free cash flow
$30.48M
Per share
Balance sheet
Liquidity
EPS
$0.08
EPS diluted
$0.08
Free cash flow per share
$0.37
Book value per share
$4.47
Revenue per share
$1.94
TBVPS
$4.79
Total assets
$393.2M
Total liabilities
$118.04M
Debt
$41.86M
Equity
$275.16M
Working capital
$273.06M
Debt to equity
0.15
Current ratio
5.61
Quick ratio
5.61
Net debt/EBITDA
-2.34
Margins
Efficiency
Dividend
EBITDA margin
11.1%
Gross margin
100%
Net margin
3.9%
Operating margin
-1.3%
Return on assets
1.7%
Return on equity
2.7%
Return on invested capital
4.7%
Return on capital employed
2.8%
Return on sales
5.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLUE stock price
How has the Monte Rosa Therapeutics stock price performed over time
Intraday
0.22%
1 week
-3.73%
1 month
16.88%
1 year
27.82%
YTD
-33.14%
QTD
0%
Financial performance
How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$159.49M
Gross profit
$159.49M
Operating income
-$2.13M
Net income
$6.15M
Gross margin
100%
Net margin
3.9%
Monte Rosa Therapeutics's revenue has surged by 111% QoQ
The gross profit has surged by 111% since the previous quarter
The net income has soared by 108% from the previous quarter and by 105% YoY
The net margin has surged by 104% since the previous quarter and by 100% year-on-year
Price vs fundamentals
How does GLUE's price correlate with its fundamentals
Growth
What is Monte Rosa Therapeutics's growth rate over time
Valuation
What is Monte Rosa Therapeutics stock price valuation
P/E
58
P/B
1.04
P/S
2.39
EV/EBIT
25.77
EV/EBITDA
13.75
EV/Sales
1.53
Monte Rosa Therapeutics's EPS has soared by 108% from the previous quarter and by 103% YoY
The equity has surged by 80% year-on-year and by 23% since the previous quarter
GLUE's P/B is 42% below its 5-year quarterly average of 1.8 and 20% below its last 4 quarters average of 1.3
Monte Rosa Therapeutics's revenue has surged by 111% QoQ
GLUE's price to sales (P/S) is 89% less than its last 4 quarters average of 21.1
Efficiency
How efficient is Monte Rosa Therapeutics business performance
The ROIC has soared by 111% from the previous quarter and by 107% YoY
Monte Rosa Therapeutics's ROA has soared by 108% from the previous quarter and by 103% YoY
GLUE's ROE has soared by 107% since the previous quarter and by 104% year-on-year
Monte Rosa Therapeutics's ROS has soared by 106% from the previous quarter and by 100% YoY
Dividends
What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLUE.
Financial health
How did Monte Rosa Therapeutics financials performed over time
The quick ratio has surged by 134% since the previous quarter and by 17% year-on-year
The company's current ratio has surged by 134% QoQ and by 16% YoY
The debt is 85% smaller than the equity
The equity has surged by 80% year-on-year and by 23% since the previous quarter
The debt to equity has plunged by 50% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.